Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial
| العنوان: | Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial |
|---|---|
| المؤلفون: | Verdonschot, Job A. J., Ferreira, João Pedro, Pellicori, Pierpaolo, Brunner-La Rocca, Hans-Peter, Clark, Andrew L., Cosmi, Franco, Cuthbert, Joe, Girerd, Nicolas, Mariottoni, Beatrice, Petutschnigg, Johannes, Rossignol, Patrick, Cleland, John G. F., Zannad, Faiez, Heymans, Stephane R. B., HOMAGE \\'Heart Omics in AGEing\\' consortium |
| المساهمون: | Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht], Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] (CIC-P), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), University of Glasgow, Institute of Health and Wellbeing, University of Glasgow-Gartnavel General Hospital, Glasgow, Robertson Centre for Biostatistics & Clinical Trials Unit, University of Hull [United Kingdom], Castle Hill Hospital, Cortona Hospital, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Charité Campus Virchow-Klinikum (CVK), Berlin Institute of Health (BIH), German Center for Cardiovascular Research (DZHK), The research leading to these results has received funding from the EuropeanUnion Commission’s Seventh Framework programme under Grant AgreementNo. 305507 (HOMAGE). S.H: This manuscript has been possible thanks to thesupport of the Netherlands Cardiovascular Research Initiative, an initiativewith support of the Dutch Heart Foundation, CVON2016-Early HFPEF, 2015-10,CVON She-PREDICTS, Grant 2017-21., European Project: 305507, Université de Lorraine (UL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM), BOZEC, Erwan, HOMAGE (Heart Omics in Ageing consortium) - 305507 - INCOMING, RS: Carim - H02 Cardiomyopathy, Cardiologie, MUMC+: MA Med Staf Spec Cardiologie (9) |
| المصدر: | Cardiovascular Diabetology Cardiovascular Diabetology, BioMed Central, 2021, 20 (1), pp.163. ⟨10.1186/s12933-021-01357-9⟩ Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-10 (2021) Cardiovascular Diabetology, 20(1):163. BioMed Central Ltd |
| بيانات النشر: | HAL CCSD, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Male, Proteomics, Cardiac & Cardiovascular Systems, Time Factors, Proteome, Diabetic Cardiomyopathies, Endocrinology, Diabetes and Metabolism, 030204 cardiovascular system & hematology, Spironolactone, chemistry.chemical_compound, 0302 clinical medicine, Risk Factors, Natriuretic peptide, Prospective Studies, Original Investigation, Mineralocorticoid Receptor Antagonists, 0303 health sciences, Diabetes, Blood Proteins, GROWTH-DIFFERENTIATION FACTOR-15, 3. Good health, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Treatment Outcome, Biomarker (medicine), Female, Cardiology and Cardiovascular Medicine, Life Sciences & Biomedicine, medicine.medical_specialty, medicine.drug_class, Heart failure, Risk Assessment, 03 medical and health sciences, Endocrinology & Metabolism, INFLAMMATION, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Predictive Value of Tests, Diabetes mellitus, Internal medicine, medicine, Diabetes Mellitus, Diseases of the circulatory (Cardiovascular) system, Humans, 030304 developmental biology, Aged, Proteomic Profile, Science & Technology, business.industry, Biomarker, medicine.disease, Omics, Fibrosis, Blood pressure, chemistry, RC666-701, Cardiovascular System & Cardiology, business, Biomarkers |
| الوصف: | Background Patients with diabetes mellitus (DM) are at increased risk of developing heart failure (HF). The “Heart OMics in AGEing” (HOMAGE) trial suggested that spironolactone had beneficial effect on fibrosis and cardiac remodelling in an at risk population, potentially slowing the progression towards HF. We compared the proteomic profile of patients with and without diabetes among patients at risk for HF in the HOMAGE trial. Methods Protein biomarkers (n = 276) from the Olink®Proseek-Multiplex cardiovascular and inflammation panels were measured in plasma collected at baseline and 9 months (or last visit) from HOMAGE trial participants including 217 patients with, and 310 without, diabetes. Results Twenty-one biomarkers were increased and five decreased in patients with diabetes compared to non-diabetics at baseline. The markers clustered mainly within inflammatory and proteolytic pathways, with granulin as the key-hub, as revealed by knowledge-induced network and subsequent gene enrichment analysis. Treatment with spironolactone in diabetic patients did not lead to large changes in biomarkers. The effects of spironolactone on NTproBNP, fibrosis biomarkers and echocardiographic measures of diastolic function were similar in patients with and without diabetes (all interaction analyses p > 0.05). Conclusions Amongst patients at risk for HF, those with diabetes have higher plasma concentrations of proteins involved in inflammation and proteolysis. Diabetes does not influence the effects of spironolactone on the proteomic profile, and spironolactone produced anti-fibrotic, anti-remodelling, blood pressure and natriuretic peptide lowering effects regardless of diabetes status. Trial registration NCT02556450. |
| وصف الملف: | Electronic; application/pdf |
| اللغة: | English |
| تدمد: | 1475-2840 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df652958d7e94ce09add8331ace3234fTest https://hal.univ-lorraine.fr/hal-03320862/documentTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....df652958d7e94ce09add8331ace3234f |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14752840 |
|---|